Monte Rosa Therapeutics
GLUE
68 hedge funds and large institutions have $281M invested in Monte Rosa Therapeutics in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 13 closing their positions.
614% more call options, than puts
Call options by funds: $685K | Put options by funds: $96K
24% more capital invested
Capital invested by funds: $227M → $281M (+$54.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.53% less ownership
Funds ownership: 80.08% → 79.55% (-0.53%)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
4% less funds holding
Funds holding: 71 → 68 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$924K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$716K |
| 3 |
Millennium Management
New York
|
+$491K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$287K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.17M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$763K |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$512K |
| 4 |
BlackRock
New York
|
-$385K |
| 5 |
HF
HRT Financial
New York
|
-$357K |
GLUE Hedge Fund Activity: Q1 2024 in Review
68 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2024, worth a combined $281M — up 24% from $227M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GLUE and 10 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $924K. The largest seller was Fidelity Investments, cutting an estimated $1.17M.
- 68 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2024, down from 71 in Q4 2023.
- Funds reported $281M of Monte Rosa Therapeutics stock for Q1 2024, up 24% quarter-over-quarter.
- 10 funds opened new Monte Rosa Therapeutics positions in Q1 2024 and 13 closed out, a net change of -3 holders.
- The largest Monte Rosa Therapeutics buyer in Q1 2024 was T. Rowe Price Associates, an estimated $924K added.
- The largest Monte Rosa Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2024.